The Middle EAST Antibodies Contract Manufacturing Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising demand for monoclonal antibodies, increasing prevalence of chronic diseases, and advancements in biopharmaceutical manufacturing technologies....